Literature DB >> 15591474

Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.

David M Rodman1, Jillian M Polis, Sonya L Heltshe, Marci K Sontag, Cathy Chacon, Rachel V Rodman, Sara J Brayshaw, Gwen A Huitt, Michael D Iseman, Milene T Saavedra, Lynn M Taussig, Jeffrey S Wagener, Frank J Accurso, Jerry A Nick.   

Abstract

Although the median survival for patients with cystic fibrosis (CF) is 32.9 years, a small group of patients live much longer. We analyzed the genotype and phenotype of CF patients 40 years and older seen between 1992 and 2004 at the National Jewish Medical and Research Center (n = 55). These patients were divided into two groups according to age at diagnosis: an early diagnosis (ED) group, median age at diagnosis 2.0 years (range 0.1-15 years, n = 28), and a late diagnosis (LD) group, median age of diagnosis 48.8 years (range 24-72.8 years, n = 27). Consistent with the hypothesis that the CFTR genotype affects the age at diagnosis, CFTR DeltaF508 homozygous individuals were more common in the ED group. Although patients in the ED group were predominantly male, the majority of LD patients were female. Patients with CF diagnosed late had a significantly lower prevalence of pancreatic insufficiency and CF-related diabetes, and better lung function. Fewer patients in the LD groups were infected with Pseudomonas aeruginosa, whereas a greater percentage had cultures positive for nontuberculous mycobacteria. This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ distinctly from survivors of long-term CF diagnosed as children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591474     DOI: 10.1164/rccm.200403-404OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

Review 1.  Update in cystic fibrosis 2005.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2006-05-01       Impact factor: 21.405

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Authors:  Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

4.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Authors:  Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

5.  Children and young adults with CF in the USA have better lung function compared with the UK.

Authors:  Christopher H Goss; Stephanie J MacNeill; Hebe B Quinton; Bruce C Marshall; Alexander Elbert; Emily A Knapp; Kristofer Petren; Elaine Gunn; Joanne Osmond; Diana Bilton
Journal:  Thorax       Date:  2014-09-25       Impact factor: 9.139

6.  Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis.

Authors:  Kimberly L Brown; Patrick A Flume
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

Review 7.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

8.  Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.

Authors:  Claire L Keating; Xinhua Liu; Emily A Dimango
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

Review 9.  A genetic perspective on granulomatous diseases with an emphasis on mycobacterial infections.

Authors:  Un-In Wu; Steven M Holland
Journal:  Semin Immunopathol       Date:  2016-01-05       Impact factor: 9.623

10.  Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005.

Authors:  Megan E Billinger; Kenneth N Olivier; Cecile Viboud; Ruben Montes de Oca; Claudia Steiner; Steven M Holland; D Rebecca Prevots
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.